查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1316815

中樞神經系統生物標記市場：按適應症、用途和最終用戶分類 - 全球預測 2023-2030

Central Nervous System Biomarkers Market by Disease Indication, Application, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球中樞神經系統生物標記市場將達43.7418億美元，年複合成長率為10.32%，大幅成長，2030年將達到873877萬美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球中樞神經系統生物標記市場至關重要。透過檢驗業務策略和產品滿意度等關鍵指標，它可以對供應商進行全面評估，使用戶能夠根據自己的特定需求做出資訊的決策。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對整體收入、客戶群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.中樞神經系統生物標記的全球市場規模和預測是多少？

2.在預測期內，COVID-19 影響全球中樞神經系統生物標記市場的阻礙因素和影響有哪些？

3.在預測期內，全球中樞神經系統生物標記市場需要投資哪些產品/細分市場/應用/領域？

4.全球中樞神經系統生物標記市場的競爭策略為何？

5.全球中樞神經系統生物標記市場的技術趨勢和法律規範是什麼？

6.全球中樞神經系統生物標記市場主要供應商的市佔率是多少？

7. 哪些型態和策略措施被認為適合進入中樞神經系統生物標記全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 肥胖增加導致神經系統疾病
      • 中樞神經系統生物標記的潛在臨床應用
      • 基因組學、蛋白質組學和成像系統的開發
    • 抑制因素
      • 檢驗成本高，報銷成本不利
    • 機會
      • 改善中樞神經系統生物標記的研發活動
      • 將重新專注於建立策略聯盟和引進新產品和技術。
    • 任務
      • 缺乏熟練的技術專家
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 中樞神經系統生物標記市場：按疾病適應症

  • 阿茲海默氏症
  • 多發性硬化症
  • 帕金森氏症
  • 創傷性腦損傷

第7章 中樞神經系統生物標記市場：用途

  • 診斷
  • 疾病風險評估
  • 藥物研發發現與開發
  • 個人化醫療

第8章 中樞神經系統生物標記市場：按最終用戶

  • 診所和醫院
  • 診斷實驗室
  • 研究中心

第9章 美洲中樞神經系統生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太中樞神經系統生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲中樞神經系統生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-450A0628CED4

The Global Central Nervous System Biomarkers Market is forecasted to grow significantly, with a projected USD 4,374.18 million in 2023 at a CAGR of 10.32% and expected to reach a staggering USD 8,738.77 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Central Nervous System Biomarkers Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Central Nervous System Biomarkers Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Indication, market is studied across Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, and Traumatic Brain Injury. The Alzheimer's Disease is projected to witness significant market share during forecast period.

Based on Application, market is studied across Diagnostics, Disease Risk Assessment, Drug Discovery & Development, and Personalized Medicines. The Drug Discovery & Development is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Clinics & Hospitals, Diagnostic Labs, and Research Centers. The Diagnostic Labs is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Central Nervous System Biomarkers Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Biomarkers Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Biomarkers Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Biomarkers Market?

4. What is the competitive strategic window for opportunities in the Global Central Nervous System Biomarkers Market?

5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Biomarkers Market?

6. What is the market share of the leading vendors in the Global Central Nervous System Biomarkers Market?

7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Biomarkers Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Central Nervous System Biomarkers Market, by Disease Indication, 2022 vs 2030
  • 4.3. Central Nervous System Biomarkers Market, by Application, 2022 vs 2030
  • 4.4. Central Nervous System Biomarkers Market, by End-User, 2022 vs 2030
  • 4.5. Central Nervous System Biomarkers Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in obesity leading to neurological illnesses
      • 5.1.1.2. Availability of central nervous system biomarkers for clinical use
      • 5.1.1.3. Development of genomics, proteomics, and imaging systems
    • 5.1.2. Restraints
      • 5.1.2.1. High validation cost and unfavorable reimbursement costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving research and development activities for central nervous system biomarkers
      • 5.1.3.2. Emerging focus on building strategic alliances and introduction of new products and technology
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled technical professionals
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Central Nervous System Biomarkers Market, by Disease Indication

  • 6.1. Introduction
  • 6.2. Alzheimer's Disease
  • 6.3. Multiple Sclerosis
  • 6.4. Parkinson's Disease
  • 6.5. Traumatic Brain Injury

7. Central Nervous System Biomarkers Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Disease Risk Assessment
  • 7.4. Drug Discovery & Development
  • 7.5. Personalized Medicines

8. Central Nervous System Biomarkers Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics & Hospitals
  • 8.3. Diagnostic Labs
  • 8.4. Research Centers

9. Americas Central Nervous System Biomarkers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Central Nervous System Biomarkers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Central Nervous System Biomarkers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
  • FIGURE 5. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 7. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET DYNAMICS
  • FIGURE 9. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 5. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 10. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 146. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 147. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET LICENSE & PRICING